Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell initiated coverage on shares of Pliant Therapeutics (NASDAQ:PLRX) in a research report sent to investors on Monday, Analyst Price Targets reports. The firm issued a buy rating and a $52.00 target price on the stock.
Shares of PLRX opened at $36.30 on Monday. Pliant Therapeutics has a fifty-two week low of $19.42 and a fifty-two week high of $43.92. The stock has a fifty day moving average of $36.44 and a two-hundred day moving average of $28.47.
Pliant Therapeutics (NASDAQ:PLRX) last released its earnings results on Monday, March 15th. The company reported ($0.54) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.71) by $0.17. Pliant Therapeutics had a return on equity of 16.55% and a net margin of 20.83%. On average, analysts forecast that Pliant Therapeutics will post -2.28 EPS for the current year.
Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in shares of Pliant Therapeutics by 466.5% during the 3rd quarter. BlackRock Inc. now owns 484,279 shares of the company’s stock valued at $10,969,000 after acquiring an additional 398,792 shares in the last quarter. State Street Corp purchased a new position in Pliant Therapeutics in the third quarter valued at about $2,723,000. Charles Schwab Investment Management Inc. acquired a new position in Pliant Therapeutics in the 3rd quarter worth about $1,428,000. Point72 Asset Management L.P. acquired a new stake in shares of Pliant Therapeutics during the 3rd quarter valued at about $1,166,000. Finally, Swiss National Bank acquired a new position in Pliant Therapeutics in the fourth quarter worth approximately $545,000. Institutional investors own 79.46% of the company’s stock.
Pliant Therapeutics Company Profile
Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avÃ6 and avÃ1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis.
Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.